15-20-3　ⓔ文献

  1. Antoniou A, Pharoah PD, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet, 2003; 72: 1117–1130.

  2. Enomoto T, Aoki D, et al: The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE). Int J Gynecol Cancer, 2019; 29: 1043–1049.

  3. Hirasawa A, Imoto I, et al: Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer. Oncotarget, 2017; 8: 112258–112267.

  4. Hori M, Matsuda T, et al: Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol, 2015; 45: 884-891.

  5. 日本産科婦人科学会，日本病理学会編：卵巣腫瘍・卵管癌・腹膜癌取扱い規約 第1版，金原出版，2015．

  6. Katsumata N, Yasuda M, et al: Japanese Gynecologic Oncology Group. Long–term results of dose–dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open–label trial. Lancet Oncol, 2013; 14: 1020–1026.

  7. Burger RA, Brady MF, et al: Gynecologic Oncology Group: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med, 2011; 365: 2473–2483.

  8. Perren TJ, Swart AM, et al: ICON7 Investigators: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med, 2011; 365: 2484–2496.

  9. Moore K, Colombo N, et al: Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med, 2018; 379: 2495–2505.

  10. González–Martín A, Pothuri B, et al: Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med, 2019; 381: 2391–2402.

  11. Domchek SM, Friebel TM, et al: Association of risk–reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA, 2010; 304: 967–975.

  12. Hirasawa A, Masuda K, et al: Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case. Jpn J Clin Oncol, 2014; 4: 49–56.

  13. 榎本隆之：婦人科腫瘍委員会報告 第60回治療年報．日本産科婦人科学会雑誌，2015; 67: 1189–1257.